Scientific Content

GOLD 2026 Report: Key Updates for COPD Management

What’s New in the GOLD 2026 Report

Understanding PIRA in MS: An Overview with Dr. Barry Singer

Progression Independent of Relapse Activity (PIRA) represents the gradual, sustained worsening of disability that occurs even without relapses. In this video, Dr. Barry Singer explains how PIRA is defined, why it affects many patients across the MS spectrum, and how clinicians can better detect subtle changes that reflect true long-term progression.

Understanding Kaplan–Meier Curves in MS: An Overview with Dr. Barry Singer

Kaplan–Meier curves play a key role in visualizing how clinical events—such as confirmed disability progression—evolve over time in MS studies. In this video, Dr. Barry Singer provides a clear, simplified walkthrough of how these curves are constructed, how patient data contributes to each step, and what curve separation really tells us about treatment impact. This resource offers an accessible foundation for anyone looking to better understand KM interpretation in MS research.

Guidelines for RSV prevention with Nirsevimab

Respiratory Syncytial Virus (RSV) is a major cause of lower respiratory tract infections in infants and young children. Nirsevimab is a long-acting monoclonal antibody that provides passive immunization against RSV, offering protection throughout the RSV season with a single dose

RSV Shield: WEQAYA's Strategy on Nirsevimab Implementation

This video explains WEQAYA's strategy on Nirsevimab Implementation

An easy guide to use Nirsevimab

ADCT – Atopic Dermatitis Control Tool

Pre-Ramadan assessment and Risk calculation for people with diabetes who want to fast during Ramadan

Rare Disease Academy 2.0/ Spotting the Signs: A guide to Early Diagnosis and a Timely Refferals

Spot early signs of Pompe, Gaucher, Fabry, ASMD & MPS I. A Sanofi guide to early diagnosis and timely referrals for rare lysosomal storage disorders.

MS pulse - Tracking the hidden drivers of MS progression

Advancing the Standard of Care: Addressing Progression in MS

An evidence-based exploration of the current MS landscape, focusing on the pathophysiology of Progression Independent of Relapse Activity (PIRA). This module examines the clinical significance of disability accumulation and the remaining unmet needs in long-term patient management.